Hims is turning into the GLP-1 middleman

New aisle, same checkout line

Hims & Hers is leaning harder into its role as the friendly neighborhood shortcut for people trying to get their hands on GLP-1 drugs without the full retail pain spiral. The company said it’s broadening access to FDA-approved weight loss treatments with lower pricing, more dosing choices, and multiple delivery formats.

The Novo nod

The biggest headline is a collaboration with Novo Nordisk, which should help open the door to Wegovy injections and oral options. That matters because the GLP-1 market has turned into a mix of demand, shortages, and “please hold” music, and Hims is trying to position itself as the smoother path through the mess.

LillyDirect gets a cameo

Hims also said providers can now prescribe meds fulfilled through independent pharmacies, including Zepbound vials, KwikPen, and Foundayo via Eli Lilly’s LillyDirect pharmacy channels. Translation: more treatment routes, more self-pay access, and more ways for Hims to keep patients inside its ecosystem instead of bouncing around between pharmacies and telehealth tabs like a caffeinated squirrel.

The bigger wrinkle: shortages

The company also flagged ongoing shortages in estrogen patches, saying it has secured inventory and will offer them through its platform. That’s a reminder that women’s healthcare supply gaps are still very real, and Hims is clearly betting that “we can actually source the stuff” is a business model, not just a slogan.

Big picture: this is Hims trying to be the supply anchor in a market that still feels a little like musical chairs — except the chairs are expensive, the music is clinical, and everybody wants GLP-1s.